Press Releases & Company Updates

Access the latest corporate news and announcements for WuXi AppTec, including business milestones, partner collaborations, quality and regulatory updates, and financial results.

Filter By

All Years

2026/10/26

WuXi AppTec Delivers Strong Q1-Q3 2026 Results and Further Raises Full-Year Guidance, Driven by Greater Success of Multiple Customers’ Products and CRDMO Model

(SHANGHAI, October 26, 2026) WuXi AppTec (Stock Codes: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first three quarters ending September 30, 2026 (“Reporting Period”). The Company further raised its full-year guidance[1], citing strong performance across revenue, profit, and cash flow driven by the greater success of multiple customers’ products and its unique integrated CRDMO platform.

2026/10/19

WuXi AppTec Receives Frost & Sullivan's Global Company of the Year Recognition in CRDMO for Tenth Consecutive Year

SHANGHAI, October 19, 2026 – WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has received Frost & Sullivan's 2026 Global Company of the Year Recognition in the CRDMO industry for the tenth consecutive year.

2026/10/07

WuXi AppTec Earns EcoVadis Gold Medal for Third Consecutive Year, Ranking Among Global Top 5% for Sustainability

SHANGHAI, October 7, 2026 – WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has received a Gold medal from EcoVadis for the third consecutive year, reflecting the Company's consistent commitment to sustainability.

2026/08/30

WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion

Shanghai, August 30, 2026 – WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), announces the distribution of its 2026 interim cash dividend. Building on its inaugural interim dividend of RMB 1.03 billion in 2025, the Company has further increased its 2026 interim dividend payout to RMB 1.51 billion. While accelerating the expansion of global capacity and capabilities, the Company remains committed to returning value to shareholders.

2026/08/03

WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance, Driven by Greater Success of Multiple Customers' Products and CRDMO Model

WuXi AppTec, a leading global pharmaceutical CRDMO, today announced financial results for the first half ending June 30, 2026. The Company raised its full-year guidance, citing strong performance across revenue, profit, and cash flow driven by the greater success of multiple customers' products and its unique integrated CRDMO platform.

1 2 3 4 ...34